Gilead Sciences (GILD) Receives Bullish Analyst Rating Amid Strong Financial Performance

Wall Street analysts have highlighted Gilead Sciences as one of the most profitable stocks due to its strong financial performance and growth in key products like Yeztugo. Truist raised its price target for GILD, citing Q1 results that beat estimates and a revised 2026 revenue outlook.

By Faheem Tahir Thu, May 21, 2026 at 8:46 PM GMT+3 3 min read · Yahoo Finance · May 21, 2026, 17:46 UTC

Tickers: $GILD $TFC

Topics: earnings beat Gilead Sciences HIV portfolio growth price target upgrade

Read the full article at Yahoo Finance

More World news

Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Pelagos Insurance Capital Reports Mixed Q3 2026 Results with Revenue Beat and EPS Miss Seeking Alpha · November 12, 2026, 18:01 UTC
Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC